Naloxone

What is Naloxone? 1

  • A pure opioid antagonist used to reverse the effects of opioid overdose, including respiratory depression, sedation, and hypotension.

Mechanism of Action & Pharmacokinetics 1

  • Competitively binds to mu, delta, kappa, and sigma opioid receptors in the CNS, reversing or preventing opioid effects.
  • Has a rapid onset of action within 1-2 minutes (IV) and a short duration of 30-60 minutes.
  • Metabolized in the liver and excreted through the kidneys.

Pharmacodynamics 1

Cardiovascular

  • Rapid reversal of opioids can cause hypertension, tachycardia, and even pulmonary edema or arrhythmias in severe cases.

Respiratory

  • Effectively reverses opioid-induced respiratory depression, restoring normal respiration.
  • Rapid administration can precipitate withdrawal symptoms in opioid-dependent individuals.

Indications 1

  • Reversal of opioid overdose, particularly in cases of respiratory depression.
  • Perioperative management of excessive sedation or respiratory depression due to opioids.

Dosage

  • Intravenous (IV):
    • Initial dose: 0.04 to 0.1 mg IV every 1-2 minutes to effect.
    • 0.25-0.5 mcg/kg in pediatrics 2
  • Intramuscular (IM):
    • 0.4 mg IM; may repeat as necessary.
  • Intranasal:
    • 4 mg as a single spray in one nostril; may repeat as necessary.
  • IV Infusion:
    • 3-10 mcg/kg/hr

Contraindications 1

  • Hypersensitivity to naloxone or any of its components.
  • Use with caution in opioid-dependent patients, as it may precipitate acute withdrawal symptoms.

Complications 1

  • Acute opioid withdrawal symptoms, including agitation, nausea, vomiting, tachycardia, and hypertension.
  • Risk of pulmonary edema, particularly in patients with pre-existing cardiac conditions.
  • Reversal of analgesia, leading to the return of pain.

References

  1. Birdi T, Sullivan P. Ottawa Anesthesia Primer. Toronto, Ontario: Echo Book Publishing; 2012.  2 3 4 5 6

  2. @alma991028143802004336 , Coté and Lerman's a practice of anesthesia for infants and children, 2018 Private or Broken Links
    The page you're looking for is either not available or private!